ADA and neoplasm: • Sustained mitigation of ADAs even after 11 challenge injections of LMB-100 alone• Did not affect immune responses to other unrelated antigens administered during challenge period• Mitigated ADA response in animals previously exposed to LMB-100• Improved survival in tumor bearing animals• Adoptive transfer of splenocytes from treated animals to naïve animals mitigates subsequent ADA formation